A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.

Klicks: 391
ID: 94114
2020
Artikelqualität & Leistungskennzahlen
Gesamtqualität Improving Quality
0.0 /100
Kombiniert Engagement-Daten mit KI-bewerteter akademischer Qualität
KI-Qualitätsbewertung
Nicht analysiert
Abstract
Hepatitis C (HCV) infection is a significant health threat, with increasing incidence rates in the setting of the opioid crisis. Many patients miss appointments and cannot initiate treatment. We implemented financial incentives to improve appointment attendance in a primary care-based HCV treatment setting.We conducted a systems-level financial incentives intervention at the Adult Primary Care HCV Treatment Program at Boston Medical Center which provides care to many patients with substance use disorders. From April 1 to June 30, 2017, we provided a $15 gift card to patients who attended appointments with an HCV treatment provider. We evaluated the effectiveness of the incentives by 1) conducting a monthly interrupted time series analysis to assess trends in attendance January 2016-September 2017; and 2) comparing the proportion of attended appointments during the intervention to a historical comparison group in the previous year, April 1 to June 30, 2016.327 visits were scheduled over the study period; 198 during the intervention and 129 during the control period. Of patient visits in the intervention group, 72.7% were attended relative to 61.2% of comparison group visits (p = 0.03). Appointments in the intervention group were more likely to be attended (adjusted odds ratio 1.94, 95% confidence interval 1.16-3.24). Interrupted time series analysis showed that the intervention was associated with an average increase of 15.4 attended visits per 100 appointments scheduled, compared to the period prior to the intervention (p = 0.01).Implementation of a financial incentive program was associated with improved appointment attendance at a safety-net hospital-based primary care HCV treatment program. A randomized trial to establish efficacy and broader implementation potential is warranted.
Referenzschlüssel
lee2020aplos Verwenden Sie diesen Schlüssel zum automatischen Zitieren im Manuskript bei Verwendung von SciMatic Manuscript Manager oder Thesis Manager
Autoren Lee, Kristen S;Quintiliani, Lisa;Heinz, Alexandra;Johnson, Natrina L;Xuan, Ziming;Truong, Ve;Lasser, Karen E;
Zeitschrift PloS one
Jahr 2020
DOI
10.1371/journal.pone.0228767
URL
Schlüsselwörter

Zitationen

Keine Zitationen gefunden. Um eine Zitation hinzuzufügen, kontaktieren Sie den Administrator unter info@scimatic.org

Noch keine Kommentare. Seien Sie der Erste, der diesen Artikel kommentiert.